Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

January 1, 2033

Study Completion Date

January 1, 2034

Conditions

KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease

Interventions

DRUG

Pacritinib

Pacritinib is administered orally as 200 mg twice daily for a total of 6, 28-day cycles

Trial Locations (1)

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH